These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21807323)

  • 1. Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance.
    Emans ME; van der Putten K; van Rooijen KL; Kraaijenhagen RJ; Swinkels D; van Solinge WW; Cramer MJ; Doevendans PA; Braam B; Gaillard CA
    J Card Fail; 2011 Aug; 17(8):626-33. PubMed ID: 21807323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
    Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between red cell distribution width with erythropoietin resistance in iron replete hemodialysis patients.
    Afsar B; Saglam M; Yuceturk C; Agca E
    Eur J Intern Med; 2013 Apr; 24(3):e25-9. PubMed ID: 23246125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil gelatinase-associated lipocalin (NGAL) in chronic cardiorenal failure is correlated with endogenous erythropoietin levels and decreases in response to low-dose erythropoietin treatment.
    Emans ME; Braam B; Diepenbroek A; van der Putten K; Cramer MJ; Wielders JP; Swinkels DW; Doevendans PA; Gaillard CA
    Kidney Blood Press Res; 2012; 36(1):344-54. PubMed ID: 23235391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio-renal anemia syndrome.
    Kato A
    Future Cardiol; 2010 Nov; 6(6):769-71. PubMed ID: 21142632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of red blood cell indices (MCV, MCH, RDW) in monitoring chronic hemodialysis patients treated with recombinant erythropoietin.
    Fialon P; Leaute AG; Sassier P; Vallot C; Wone C
    Pathol Biol (Paris); 1993 Dec; 41(10):931-5. PubMed ID: 8159473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study.
    van der Putten K; Jie KE; Emans ME; Verhaar MC; Joles JA; Cramer MJ; Velthuis BK; Meiss L; Kraaijenhagen RJ; Doevendans PA; Braam B; Gaillard CA
    J Nephrol; 2010; 23(4):363-8. PubMed ID: 20383871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red blood cell distribution width predicts new-onset anemia in heart failure patients.
    Pascual-Figal DA; Bonaque JC; Manzano-Fernández S; Fernández A; Garrido IP; Pastor-Perez F; Lax A; Valdes M; Januzzi JL
    Int J Cardiol; 2012 Oct; 160(3):196-200. PubMed ID: 21555160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure.
    van der Putten K; Braam B; Jie KE; Gaillard CA
    Nat Clin Pract Nephrol; 2008 Jan; 4(1):47-57. PubMed ID: 18094727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction.
    Okonko DO; Marley SB; Anker SD; Poole-Wilson PA; Gordon MY
    Int J Cardiol; 2013 Apr; 164(3):359-64. PubMed ID: 21821297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red cell distribution width as a marker of impaired exercise tolerance in patients with chronic heart failure.
    Van Craenenbroeck EM; Pelle AJ; Beckers PJ; Possemiers NM; Ramakers C; Vrints CJ; Van Hoof V; Denollet J; Conraads VM
    Eur J Heart Fail; 2012 Jan; 14(1):54-60. PubMed ID: 22027082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
    Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
    Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes.
    Comín-Colet J; Ruiz S; Cladellas M; Rizzo M; Torres A; Bruguera J
    J Card Fail; 2009 Nov; 15(9):727-35. PubMed ID: 19879457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure.
    Bolger AP; Bartlett FR; Penston HS; O'Leary J; Pollock N; Kaprielian R; Chapman CM
    J Am Coll Cardiol; 2006 Sep; 48(6):1225-7. PubMed ID: 16979010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
    Wang W; Zhang MH; Yu Y; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
    Daschner M; Mehls O; Schaefer F
    Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients.
    van der Putten K; Jie KE; van den Broek D; Kraaijenhagen RJ; Laarakkers C; Swinkels DW; Braam B; Gaillard CA
    Eur J Heart Fail; 2010 Sep; 12(9):943-50. PubMed ID: 20601671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
    Palazzuoli A; Silverberg DS; Iovine F; Calabrò A; Campagna MS; Gallotta M; Nuti R
    Am Heart J; 2007 Oct; 154(4):645.e9-15. PubMed ID: 17892986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease.
    Guerrero-Riscos MÁ; Montes-Delgado R; Seda-Guzmán M; Praena-Fernández JM
    Nefrologia; 2012 May; 32(3):343-52. PubMed ID: 22535158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.